Hepion Pharmaceuticals Ends Merger Agreement With Pharma Two B Ltd.

Hepion Pharmaceuticals, Inc., a clinical-stage biopharma company focused on treatments for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases, announced today that it has mutually agreed with Pharma Two B Ltd. to terminate their merger agreement, initially signed on July 19, 2024. As part of the agreement, neither party will incur a termination fee, marking a mutual decision to end the merger talks.

Hepion Pharmaceuticals, Inc., has announced the cancellation of its special stockholder meeting that was originally scheduled for December 12, 2024. Additionally, the company has withdrawn the proposals outlined in its Definitive Proxy Statement on Form F-4, which was filed with the U.S. Securities and Exchange Commission on November 8, 2024, from consideration by its stockholders.